Yong Lin

Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics

Indianapolis

United States

SCHOLARLY PAPERS

1

DOWNLOADS

106

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Number of pages: 38 Posted: 18 Mar 2022
Shanghai Jiao Tong University (SJTU) - Shanghai Lung Cancer Center, Zhengzhou University - Henan Provincial People's Hospital, Shanghai Jiao Tong University (SJTU) - Department of Medical Oncology, Jilin Cancer Hospital - Department of Oncology, Zhengzhou University - Henan Cancer Hospital, Peking University - Department of Thoracic Medical Oncology, Peking University - Department of Thoracic Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Shandong First Medical University - Department of Oncology, Xuzhou Central Hospital, Nanjing University - Department of Respiratory Medicine, Hebei Medical University, Jilin University (JLU) - Cancer Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Zhengzhou University - Department of Oncology, Xiamen University, Nanjing University, Sichuan University - Department of Respiratory and Critical Care Medicine, Qingdao University - Affiliated Hospital, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information, Eli Lilly and Company, Ltd - Department of Oncology Medical Strategy, Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information and Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology
Downloads 106 (552,802)

Abstract:

Loading...

sintilimab, IBI305, NSCLC, EGFR